You are leaving Medscape Education
Cancel Continue
Log in to save activities Your saved activities will show here so that you can easily access them whenever you're ready. Log in here CME & Education Log in to keep track of your credits.



Current Practice Patterns in Schizophrenia: Show What You Know

  • Authors: Christoph U. Correll, MD
  • CME / ABIM MOC / CE Released: 2/10/2023
  • Valid for credit through: 2/10/2024
Start Activity

  • Credits Available

    Physicians - maximum of 0.25 AMA PRA Category 1 Credit(s)™

    ABIM Diplomates - maximum of 0.25 ABIM MOC points

    Nurses - 0.25 ANCC Contact Hour(s) (0.25 contact hours are in the area of pharmacology)

    You Are Eligible For

    • Letter of Completion
    • ABIM MOC points

Target Audience and Goal Statement

This activity is intended for psychiatrists, primary care physicians, obstetricians and gynecologists, nurse practitioners, physician assistants, nurses, and other clinicians who treat patients with schizophrenia.

The goal of this activity is for learners to be better able to identify clinical practice gaps in the recognition and management of schizophrenia and be better able to assess their learning needs in schizophrenia care and advancements in treatment.

Upon completion of this activity, participants will:

  • Have increased knowledge regarding the
    • Potential of investigational therapies to fill unmet needs in schizophrenia care
  • Self-assess learning needs related to
    • Individualized selection of antipsychotic therapies for patients with schizophrenia


Medscape, LLC requires every individual in a position to control educational content to disclose all financial relationships with ineligible companies that have occurred within the past 24 months. Ineligible companies are organizations whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients.

All relevant financial relationships for anyone with the ability to control the content of this educational activity are listed below and have been mitigated. Others involved in the planning of this activity have no relevant financial relationships.

Disclosures for additional planners can be found here.


  • Christoph U. Correll, MD

    Professor of Psychiatry and Molecular Medicine
    Zucker School of Medicine at Hofstra
    Northwell, New York
    Professor of Child and Adolescent Psychiatry 
    Charité University Medicine 
    Berlin, Germany 


    Christoph U. Correll, MD, has the following relevant financial relationships: 
    Consultant or advisor for: AbbVie Inc.; ACADIA Pharmaceuticals Inc.; Alkermes, Inc.; Allergan, Inc.; Angelini Pharma; Aristo Pharma; Boehringer Ingelheim Pharmaceuticals, Inc.; Cardio Diagnostics; Cerevel Therapeutics; CNX Therapeutics; Compass Pathways; Darnitsa; Gedeon Richter; Hikma Pharmaceuticals; Holmusk; Intra-Cellular Therapies, Inc.; Janssen/Johnson and Johnson; Karuna Therapeutics; LB Pharma; Lundbeck, Inc.; MedAvante-ProPhase; MedinCell; Merck; Mindpax; Mitsubishi Tanabe Pharma Corporation; Mylan Laboratories Inc.; Neurocrine Biosciences, Inc.; Newron Pharmaceuticals SPA; Noven Pharmaceuticals, Inc.; Otsuka Pharmaceutical Co., Ltd.; Pharmabrain; PPD Biotech; Recordati; Relmada Therapeutics, Inc.; Reviva Pharmaceuticals Inc.; ROVI; Seqirus; SERVIER; SK Life Science; Sunovion Pharmaceuticals Inc.; Sun Pharmaceutical Industries, Ltd.; Supernus Pharmaceuticals, Inc.; Takeda Pharmaceutical Company; Teva Pharmaceuticals; Viatris
    Speaker or member of speakers bureau for: AbbVie Inc.; Angelini; Aristo Pharma; Darnitsa; Gedeon Richter; Hikma Pharmaceuticals; Intra-Cellular Therapies, Inc.; Janssen/Johnson and Johnson; Lundbeck, Inc.; Mitsubishi Tanabe Pharma Corporation; Mylan Laboratories Inc.; Otsuka Pharmaceutical Co., Ltd.; Recordati; Seqirus; Sunovion Pharmaceuticals, Inc.; Takeda Pharmaceutical Company; Viatris
    Research funding from: Janssen; Takeda Pharmaceutical Company
    Stock options from: Cardio Diagnostics; LB Pharma; Mindpax; Quantic


  • Frances McFarland, PhD, MA

    Medical Education Director, Medscape, LLC


    Frances McFarland, PhD, MA, has no relevant financial relationships.

  • Megan Breuer, PhD

    Medical Writer, Medscape, LLC


    Megan Breuer, PhD, has the following relevant financial relationships: 
    Consultant/advisor: Paratek Pharmaceuticals Inc. (former)
    Owns stock (publicly traded) in: Bristol Myers Squibb Company; Johnson & Johnson; Paratek Pharmaceuticals Inc.; Vertex Pharmaceuticals Inc.

Compliance Reviewer/Nurse Planner

  • Stephanie Corder, ND, RN, CHCP

    Associate Director, Accreditation and Compliance, Medscape, LLC


    Stephanie Corder, ND, RN, CHCP, has no relevant financial relationships.

Peer Reviewer

This activity has been peer reviewed and the reviewer has no relevant financial relationships.

Accreditation Statements

In support of improving patient care, Medscape, LLC is jointly accredited with commendation by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

    For Physicians

  • Medscape, LLC designates this enduring material for a maximum of 0.25 AMA PRA Category 1 Credit(s)™ . Physicians should claim only the credit commensurate with the extent of their participation in the activity.

    Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 0.25 MOC points in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit. Aggregate participant data will be shared with commercial supporters of this activity.

    Contact This Provider

    For Nurses

  • Awarded 0.25 contact hour(s) of nursing continuing professional development for RNs and APNs; 0.25 contact hours are in the area of pharmacology.

    Contact This Provider

For questions regarding the content of this activity, contact the accredited provider for this CME/CE activity noted above. For technical assistance, contact [email protected]

Instructions for Participation and Credit

There are no fees for participating in or receiving credit for this online educational activity. For information on applicability and acceptance of continuing education credit for this activity, please consult your professional licensing board.

This activity is designed to be completed within the time designated on the title page; physicians should claim only those credits that reflect the time actually spent in the activity. To successfully earn credit, participants must complete the activity online during the valid credit period that is noted on the title page. To receive AMA PRA Category 1 Credit™, you must receive a minimum score of 70% on the post-test.

Follow these steps to earn CME/CE credit*:

  1. Read about the target audience, learning objectives, and author disclosures.
  2. Study the educational content online or print it out.
  3. Online, choose the best answer to each test question. To receive a certificate, you must receive a passing score as designated at the top of the test. We encourage you to complete the Activity Evaluation to provide feedback for future programming.

You may now view or print the certificate from your CME/CE Tracker. You may print the certificate, but you cannot alter it. Credits will be tallied in your CME/CE Tracker and archived for 6 years; at any point within this time period, you can print out the tally as well as the certificates from the CME/CE Tracker.

*The credit that you receive is based on your user profile.


Current Practice Patterns in Schizophrenia: Show What You Know

Authors: Christoph U. Correll, MDFaculty and Disclosures

CME / ABIM MOC / CE Released: 2/10/2023

Valid for credit through: 2/10/2024



  1. Correll CU, et al. Negative symptoms in schizophrenia: a review and clinical guide for recognition, assessment, and treatment. Neuropsychiatr Dis Treat. 2020;16:519-534.
  2. Correll CU, et al. Cariprazine in the management of negative symptoms of schizophrenia: state of the art and future perspectives. Future Neurol. 2020;15:4.
  3. Sellgren CM, et al. Increased synapse elimination by microglia in schizophrenia patient-derived models of synaptic pruning. Nat Neurosci. 2019;22:374-385.
  4. Tandon R, et al. Definition and description of schizophrenia in the DSM-5. Schizophr Res. 2013;150:3-10.
  5. The American Psychiatric Association. The American Psychiatric Association Practice Guideline for the Treatment of Patients With Schizophrenia. 3rd ed. The American Psychiatric Association; 2021.
  6. Park SC, et al. Factor structure of the clinician-rated dimensions of psychosis symptom severity in patients with schizophrenia. Psychiatry Investig. 2016;13:253-254.
  7. Correll CU, et al. Emerging treatments in schizophrenia. J Clin Psychiatry. 2022;83:SU21204IP1.
  8. Foster DJ, et al. Targeting muscarinic receptors to treat schizophrenia. Behav Brain Res. 2021;405:113201.
  9. Galling B, et al. Efficacy and safety of antidepressant augmentation of continued antipsychotic treatment in patients with schizophrenia. Acta Psychiatr Scand. 2018;137:187-205.
  10. Vernon JA, et al. Antidepressants for cognitive impairment in schizophrenia -- a systematic review and meta-analysis. Schizophr Res. 2014;159:385-394.
  11. Krystal JH, et al. Emraclidine, a novel positive allosteric modulator of cholinergic M4 receptors, for the treatment of schizophrenia: a two-part, randomised, double-blind, placebo-controlled, phase 1b trial. Lancet. 2023;400:2210-2220.
  12. Correll CU, et al. Effects of olanzapine combined with samidorphan on weight gain in schizophrenia: a 24-week phase 3 study. Am J Psychiatry. 2020;177:1168-1178.
  13. Marteene W, et al. Strategies to counter antipsychotic-associated weight gain in patients with schizophrenia. Expert Opin Drug Saf. 2019;18:1149-1160.
  14. Citrome L, et al. Sublingual dexmedetomidine for the treatment of acute agitation in adults with schizophrenia or schizoaffective disorder: a randomized placebo-controlled trial. J Clin Psychiatry. 2022;83:22m14447.
  15. Fleischhacker WW, et al. Efficacy and safety of the novel glycine transporter inhibitor BI 425809 once daily in patients with schizophrenia: a double-blind, randomised, placebo-controlled phase 2 study. Lancet Psychiatry. 2021;8:191-201.
  16. Correll CU, et al. Safety and effectiveness of ulotaront (SEP-363856) in schizophrenia: results of a 6-month, open-label extension study. NPJ Schizophr. 2021;7:63.
  17. Brannan SK, et al. Muscarinic cholinergic receptor agonist and peripheral antagonist for schizophrenia. N Engl J Med. 2021;384:717-726.
  18. Correll CU, et al. Safety and tolerability of KarXT (xanomeline-trospium) in a phase 2, randomized, double-blind, placebo-controlled study in patients with schizophrenia. Schizophrenia (Heidelb). 2022;8:109.
  19. Bugarski-Kirola D, et al. Pimavanserin for negative symptoms of schizophrenia: results from the ADVANCE phase 2 randomised, placebo-controlled trial in North America and Europe. Lancet Psychiatry. 2022;9:46-58.
« Return to: Current Practice Patterns in Schizophrenia: Show What You Know
  • Print